A Partially Purified Acinetobacter baumannii Phage Preparation Exhibits no Cytotoxicity in 3T3 Mouse Fibroblast Cells

Area of Science:

• Microbiology
• Virology
• Biotechnology

Background:

• Antibiotic resistance is a growing global health concern, increasing the need for alternative treatments.
• Bacteriophages (phages) are viruses that infect bacteria and are being explored as a therapeutic alternative.
• Concerns regarding the safety and efficacy of phage therapy persist, necessitating rigorous evaluation.

Purpose of the Study:

• To assess the cytotoxic effects of Acinetobacter baumannii phage BS46 on mammalian cells.
• To determine the safety profile of phage BS46 for potential therapeutic applications.

Main Methods:

• Mouse fibroblast 3T3 cells were exposed to varying concentrations of phage BS46 (up to 2 × 10^9 pfu/mL).
• Cytotoxicity was evaluated using four distinct assays: trypan blue exclusion, Hoechst/propidium iodide staining, lactate dehydrogenase release, and the MTS assay.
• Cell viability was assessed after 24 hours of exposure.

Main Results:

• Across all four assays, phage BS46 demonstrated minimal to no impact on the viability of 3T3 cells at concentrations up to 2 × 10^9 pfu/mL.
• The results indicate that phage BS46 is non-cytotoxic to the tested mammalian cell line.
• No significant adverse effects on cell viability were observed after 24 hours of exposure.

Conclusions:

• Phage BS46 exhibits a favorable safety profile, showing no significant cytotoxicity in mouse fibroblast cells.
• These findings support the further development of phage BS46 as a potential therapeutic agent against Acinetobacter baumannii infections.
• The study underscores the importance of robust quality assurance protocols for bacteriophage therapeutics to ensure safety and efficacy.